Pharmacokinetics and pharmacodynamics of MEDI4736, a fully human anti-programmed death ligand 1 (PD-L1) monoclonal antibody, in combination with tremelimumab in patients with advanced non-small cell lung cancer (NSCLC)

e14010 Background: MEDI4736 is a human IgG1 mAb that blocks PD-L1 binding to PD-1 and CD-80 with high affinity and selectivity. Tremelimumab is a selective human IgG2 mAb inhibitor of CTLA-4 that p...